Risk of bias assessment of sequence generation : a study of 100 systematic reviews of trials by Wuytack, Francesca et al.
RESEARCH Open Access
Risk of bias assessment of sequence
generation: a study of 100 systematic
reviews of trials
Francesca Wuytack1* , Maria Regan2, Linda Biesty3, Pauline Meskell4, Jennifer E. Lutomski5, Martin O’Donnell2,
Shaun Treweek6 and Declan Devane3
Abstract
Background: Systematic reviews of randomised trials guide policy and healthcare decisions. Yet, we observed that
some reviews judge randomised trials as high or unclear risk of bias (ROB) for sequence generation, potentially
introducing bias. However, to date, the extent of this issue has not been well examined. We evaluated the
consistency in the ROB assessment for sequence generation of randomised trials in Cochrane and non-Cochrane
reviews, and explored the reviewers’ judgement of the quality of evidence for the related outcomes.
Methods: Cochrane intervention reviews (01/01/2017–31/03/2017) were retrieved from the Cochrane Database of
Systematic Reviews. We also searched for systematic reviews in ten general medical journals with highest impact
factors (01/01/2016–31/03/2017). We examined the proportion of reviews that rated the sequence generation
domain as high, low or unclear risk of selection bias. For reviews that had rated any randomised trials as high or
unclear risk of bias, we examined the proportion that had assessed the quality of evidence.
Results: Overall, 100 systematic reviews were included in our analysis. We evaluated 64 Cochrane reviews which
comprised of 984 randomised trials; 0.8% (n = 8) and 52.2% (n = 514) were rated as high and unclear ROB for
sequence generation respectively. We further evaluated 36 non-Cochrane reviews which comprised of 1376 trials;
5.8% (n = 80) and 39.6% (n = 545) were rated as high and unclear ROB respectively. Ninety percent (n = 10) of non-
Cochrane reviews which rated randomised trials as high ROB for sequence generation did not report an underlying
reason. All Cochrane reviews assessed the quality of evidence (GRADE). For the non-Cochrane reviews, only just
over half had assessed the quality of evidence.
Conclusion: Systematic reviews of interventions frequently rate randomised trials as high or unclear ROB for
sequence generation. In general, Cochrane reviews were more transparent than non-Cochrane reviews in ROB and
quality of evidence assessment. The scientific community should more strongly promote consistent ROB
assessment for sequence generation to minimise selection bias and support transparent quality of evidence
assessment. Consistency ensures that appropriate conclusions are drawn from the data.
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Background
Systematic reviews are a summary of the best available
evidence and, as a result, may shape policy and help in-
form healthcare decisions [1]. Randomised trials are
regarded as the optimal design to evaluate the effective-
ness of healthcare interventions, and thus systematic re-
views of intervention trials are an indisputable asset to
clinical decision-making and evidence-based practice [2].
Generation of a sequence of random numbers is an es-
sential component of randomisation and determines
which groups trial participants are allocated to and, when
used alongside effective allocation concealment, minimises
the risk of selection bias [2]. Effective randomisation mini-
mises bias in effect estimates, whereas inadequate ran-
domisation may exaggerate treatment effects [3–5]. The
Cochrane risk of bias (ROB) tool for interventions in-
cludes seven domains on which biases within trials are
assessed, i.e. (1) sequence generation, (2) allocation con-
cealment, (3) blinding of participants and personnel, (4)
blinding of outcome assessment, (5) incomplete outcome
data, (6) selective reporting and (7) any other [2]. If a sys-
tematic review of randomised trials states explicitly that
non-randomised trials are excluded, then one would ex-
pect that sequence generation was truly random and
therefore at low ROB for sequence generation. However,
we have observed that some Cochrane and non-Cochrane
reviews which a priori exclude non-randomised trials still
report sequence generation as high or unclear ROB for
some trials. Whereas a judgement of unclear ROB may be
due to poor reporting in primary studies, it creates uncer-
tainty whether non-randomised trials were truly excluded
from the review. A judgement of high ROB for sequence
generation suggests that non-randomised studies have
likely been included.
Cochrane reviews and some non-Cochrane reviews au-
thors now also judge the quality of evidence for the primary
and sometimes secondary outcomes using the Grading of
Recommendations Assessment, Development and Evalu-
ation system (GRADE) (http://www.gradeworkinggrou
p.org/) or an equivalent assessment tool. A GRADE profile
is performed for each outcome and includes an assessment
of study limitations and subsequent downgrading if appro-
priate. If there is high ROB in trials examining a particular
outcome, the GRADE quality of evidence would be down-
graded due to study limitations. Thus, inconsistencies in
ROB assessment can potentially impact the quality of evi-
dence judgement which in turn could affect subsequent
recommendations for practice and research.
In this paper, we examine the consistency in the ROB
assessment of the sequence generation domain of the
Cochrane ROB tool for randomised trials in Cochrane
and non-Cochrane reviews that use this tool, and, if con-
ducted, we further explored the authors’ judgement of
the quality of evidence for the related outcomes.
The objectives of this study were:
1. To determine the proportion of reviews that state
they include randomised trials only and judge
trial(s) as high ROB or unclear ROB for sequence
generation (and reason why, if given)
2. To examine if included reviews conducted a quality
of evidence assessment for the primary outcomes
3. To describe if review authors downgraded the
quality of evidence for study limitations in the
presence of studies rated as high/unclear ROB for
sequence generation, including an examination of
the reported justification
4. To compare Cochrane and non-Cochrane reviews
in relation to objectives 1 and 3
Methods
A descriptive cross-sectional survey of the ROB assess-
ment domain of sequence generation in Cochrane and
non-Cochrane reviews of randomised trials. No ethical
approval was required since this study used data already
in the public domain.
Data collection and extraction
Cochrane reviews of intervention studies published in
the first quarter of 2017 were identified and retrieved
from the Cochrane Database of Systematic Reviews. In
addition, we manually searched for and included system-
atic reviews published between April 2016 and March
2017 in ten general medical journals with the highest
impact factors (IF) based on the Thomson Reuters 2015
ranking. These were New England Journal of Medicine
(IF 59.558); Lancet (IF 44.002); JAMA (IF 37.684); BMJ
(IF 19.697); Annals of Internal Medicine (IF 16.593);
JAMA Internal Medicine (IF 14.000); PLOS Medicine
(IF 13.585); BMC Medicine (IF 8.005); Journal of In-
ternal Medicine (IF 7.803); and the Canadian Journal of
Medicine (IF 6.724).
Only systematic reviews of randomised trials were in-
cluded. Overviews of reviews, non-intervention reviews,
intervention reviews of non-randomised trials and narra-
tive reviews were excluded. Data were extracted using a
purposefully designed data extraction form. Data were
extracted on (1) Cochrane group (if applicable), journal
(if applicable) and country of lead author; (2) scope
(study designs included); (3) the number of included tri-
als; (4) the number and percentage of randomised trials
judged as high, low and unclear ROB for the sequence
generation domain and the accompanying justification;
(4) whether sensitivity analyses were conducted and, if
so, the criteria used; and (5) the GRADE quality of evi-
dence rating for all primary outcomes and whether the
authors downgraded the quality, including the justifica-
tion given by the review authors.
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Data analysis
We examined the sequence generation domain of the
Cochrane ROB tool using descriptive statistics, including
the proportions of randomised trials that were rated as
high, low or unclear ROB for this domain. For reviews
that rated any randomised trials as high ROB for se-
quence generation, the justification was examined and
compared to guidance provided in the Cochrane hand-
book [2]. Any discrepancies were reported descriptively.
We excluded non-Cochrane reviews from the analysis
that used a tool to assess ROB other than the Cochrane
ROB tool or that did not examine ROB to allow for ap-
propriate comparison with Cochrane reviews.
For reviews that had rated any randomised trials as
having high or unclear ROB for sequence generation, we
examined the proportion that downgraded the quality of
evidence (GRADE) for study limitations for all primary
outcomes that included these high/unclear ROB studies.
If the review authors had downgraded for study limita-
tions, the reported justification was examined. We also
examined the proportion of reviews that conducted sen-
sitivity analysis by ROB.
We carried out the above analyses on (1) all reviews, (2)
Cochrane reviews only and (3) non-Cochrane review only.
Results
Search results
We identified 116 Cochrane reviews published between
1 October 2016 and 31 March 2017, of which 64 reviews
were included in this study. We excluded 4 overviews of
reviews, 3 diagnostic test accuracy reviews, 1 qualitative
review/meta-synthesis, 2 screening reviews and 1 risk re-
view. Thirty-nine reviews included non-randomised tri-
als and were also excluded. Two Cochrane reviews were
‘empty’ reviews with no included studies. We identified
158 non-Cochrane reviews, of which 36 reviews had
used the Cochrane ROB tool and were included in the
final analysis. One review included individual patient
data [6]. One of the included reviews did not report suf-
ficient data; we contacted the authors but did not receive
a response [7]. The search results and reasons for exclu-
sion are presented in Fig. 1.
Risk of bias of sequence generation for randomised trials
The proportions of randomised trials rated as high, un-
clear and low ROB across all reviews are presented in
Table 1 and Fig. 2. Fewer randomised trials were rated
as having high ROB for sequence generation in
Cochrane reviews (0.8%; n = 8) than in non-Cochrane re-
views (5.8%; n = 80). The Cochrane review authors’ justi-
fications for rating these eight randomised trials (across
five reviews) as high ROB for sequence generation are
presented in Table 2. All five reviews reported why the
studies involved were rated as high ROB for sequence
generation. However, when examining the reasons given,
one review had rated a study as high ROB for sequence
generation, but the justification said there was a lack of
information reported, which would have been more ap-
propriately rated as ‘unclear’ ROB [8]. The justification
of one study [9] relates more to ROB related to alloca-
tion concealment than sequence generation.
Eighty randomised trials across 11 non-Cochrane re-
views were rated as high ROB for sequence generation.
The reasons for judging these studies as high ROB for
sequence generation are provided in Table 3. Ten of the
11 reviews did not report why the studies involved were
rated high ROB for sequence generation. Around half of
randomised trials in both Cochrane (52.2%; n = 514) and
non-Cochrane (39.6%; n = 545) were rated as unclear
ROB for sequence generation.
Quality of evidence assessment
All Cochrane reviews used the GRADE approach to
examine the quality of evidence for each outcome. For
the Cochrane reviews that included only randomised tri-
als in their scope, 52.6% (n = 30) of reviews that had
rated one or more randomised trials as high or unclear
ROB for sequence generation had downgraded the qual-
ity of evidence for the corresponding primary outcomes
(Table 4). Only two Cochrane reviews clearly reported
which ROB domains (e.g. random sequence generation)
contributed to the downgrading and provided a detailed
statement of the number/size of studies that contributed
to their judgement [9, 10]. Moreover, 17 (29.8%) of the
reviews had conducted sensitivity analysis by ROB and
22 (38.6%) had planned sensitivity analysis by ROB but
were unable to carry out the analysis due to insufficient
data or because all included studies were of high ROB.
For the non-Cochrane reviews, 20.8% (n = 5) of re-
views that had rated at least one randomised trial as high
or unclear ROB for sequence generation had down-
graded the quality of evidence for the corresponding
outcomes (Table 5). Only one non-Cochrane review that
had rated at least one randomised trial as high or un-
clear ROB for sequence generation had conducted sensi-
tivity analysis by ROB [11].
Discussion
Cochrane reviews judged randomised trials as high risk
of bias for sequence generation less frequently compared
to non-Cochrane reviews. More importantly, the reasons
for this judgement were always reported, while only one
of the ten non-Cochrane reviews reported the reason for
rating some randomised trials as high ROB for sequence
generation in their published material. This is likely to
be attributed to the highly structured approach of con-
ducting and reporting Cochrane reviews and the word
count of other journals might limit authors’ ability to
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provide more detail. Nevertheless, it is beneficial to the
research community to report this information in sup-
plementary documents.
Approximately half of reviews, both Cochrane and
non-Cochrane, judged at least one randomised trial as
having unclear ROB for sequence generation. A lack of
reporting in primary studies does not allow review authors
to assess whether randomisation was adequate. Poor
reporting is likely to be a greater issue in older studies,
prior to the publication of reporting guidelines, although
we did not stratify studies by year of publication for the
purpose of this study. We only included non-Cochrane re-
views that used the Cochrane ROB tool for comparison;
subsequently, the full extent of ROB of sequence gener-
ation for the remaining body of evidence that used an-
other tool or did not examine ROB was not examined.
Adequate randomisation together with allocation con-
cealment minimise selection bias [3], which, if present,
should be taken into account in the conclusions of the
reviews. The assessment of the quality of evidence for
individual outcomes can facilitate this process in a trans-
parent way by appropriately downgrading the quality of
Table 1 Risk of bias judgement for sequence generation of randomised trials in Cochrane and non-Cochrane reviews
Sequence generation ROB judgement of randomised trials High ROB Low ROB Unclear ROB
Cochrane reviewsa 8 (0.8%) 462 (47.0%) 514 (52.2%)
Non-Cochrane review using Cochrane ROB toolb 80 (5.8%) 751 (54.6%) 545 (39.6%)
aSixty-four reviews, including 984 randomised trials
bThirty-six reviews, including 1376 studies; one review is awaiting classification and contains an additional 35 randomised trials
Fig. 1 Search and selection flowchart
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Fig. 2 Risk of bias for sequence generation
Table 2 Reasons for rating randomised trials as high ROB for sequence generation in Cochrane reviews
Review Number of randomised trials rated as high ROB
for sequence generation (% of total included
randomised trials)
Justification for high ROB for sequence generation
(as stated by the review authors)
Lund
et al. [13]
3 (75%) Altinli 2007: “Participants were randomised into 2 groups, according
to the day the participant was first seen in the clinic (odd and even days).”
Sozen 2011a: “The participants were randomised into 2 groups—drained
and fibrin sealant—according to the admission protocol number. Details of
this protocol number unclear.”
Sozen 2011b: “The participants were randomised into two groups, drained
and non-drained, according to the admission protocol number.
Nature of this protocol number unclear.”
Cheng
et al. [9]
1 (16.7%) Randomisation may have not been executed properly as there was a large difference
in the number of participants in each arm; the acupuncture arm had 25/109 (40%)
more participants than the control group. A random number table was used to
generate sequence. Odd numbers were allocated to treatment group, even numbers
were allocated to control group.
Chauhan
et al. [14]
1 (2.7%) Participants were randomised to 2 groups according to their order of presentation
at the outpatient clinic.
McCaughan
et al. [15]
1 (16.7%) The randomisation protocol was compromised by selecting patients serially
as they registered.
Menting
et al. [8]
2 (6.9%) Czibik-stable 2008 and Czibik-unstable 2008: “Randomisation not reported”
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evidence on which conclusions are based. Our findings
show that slightly more than half of Cochrane reviews
that included randomised trials of unclear or high ROB
for sequence generation had downgraded the quality of
evidence. This proportion was lower in non-Cochrane
reviews; approximately one fifth of non-Cochrane re-
views had adjusted the quality of evidence. However, in
interpreting these findings, it is important to take into
account that the decision to downgrade the quality of
evidence is based on multiple factors, and including
studies with high/unclear ROB for sequence generation
does not necessarily indicate that downgrading is war-
ranted. Whether or not the reviews should or should not
have downgraded for study limitations is therefore un-
certain, particularly since this is a judgement and the
GRADE guidance to assess the quality of evidence is not
rigid. When we examined the justification for downgrad-
ing, nearly all reviews only stated that they downgraded
for study limitations due to (very) serious ROB, and,
even if the specific types of bias (e.g. selection bias) that
contributed to the decision to downgrade were reported
in some reviews, only two Cochrane reviews provided
further details with regards to the number/size of in-
cluded studies that had biases. This suggests that trans-
parency of the decision to downgrade is often lacking,
even in Cochrane reviews.
The findings of our study raise questions about the con-
duct of systematic reviews, more specifically the ROB and
quality of evidence assessment. We hope our findings will
generate a debate concerning some key emerging issues
for systematic review methodology. First, whether a study
should be considered a randomised trial just because the
study authors identified their study as a randomised trial,
or whether this should be based on an assessment of the
reporting of the methodological components required to
classify as a randomised trial. This has implications for
study selection in systematic reviews that include only
randomised trials. Secondly, this study underscores that
assessing quality of evidence for the outcome of interest
could lead to better judgement of review findings and
more accurately inform conclusions. All Cochrane reviews
had conducted a quality of evidence assessment, reflecting
Table 3 Reasons for rating randomised trials as high ROB for sequence generation in non-Cochrane reviews
Review Number of randomised trials rated as high ROB
for sequence generation
(% of total included randomised trials)
Reason for high ROB for sequence generation
(as stated by the review authors)
Faruque
et al. [16]
32 (28.8%) (Not reported by review authors)
Hollingsworth
et al. [17]
1 (1.8%) (Not reported by review authors)
Cipriani
et al. [18]
1 (2.9%) (Not reported by review authors)
Collister
et al. [19]
1 (5.9%) (Not reported by review authors)
Eng et al. [20] 15 (51.7%) (Not reported by review authors)
Franco
et al. [21]
4 (6.5%) (Not reported by review authors)
Hazlewood
et al. [22]
8 (5.1%) (Not reported by review authors)
Khera
et al. [23]
1 (3.6%) (Not reported by review authors)
Subramaniam
et al. [24]
9 (10.5%) (Not reported by review authors)
Schandelmaier
et al. [25]
2 (7.7%) Leung 2004: “Quasi randomised based on sequence of admission,
Urita 2013: Used odd even system for treatment allocation”
Sukkar et al. [10] 6 (7.1%) (Not reported by review authors)
Table 4 Quality of evidence and sensitivity analysis in Cochrane reviews
Rated any randomised trials as
high/unclear ROB for sequence
generation
Downgraded for study
limitations
(additional reasons not specified)
Downgraded for
study limitations
(selection bias)
Sensitivity analysis
based on ROB
(conducted)
Sensitivity analysis based
on ROB
(planned; not able to conduct)
Cochrane reviews (n = 57)a 23 (40.4%) 7 (12.3%) 17 (29.8%) 22 (38.6%)
aThree of the 57 (5.3%) reviews did not downgrade at all and rated quality of evidence as high; 23 of the 57 (40.4%) reviews only downgraded for factors other
than selection bias (other study limitations or other domains of the Cochrane ROB tool); 1 (1.8%) review did not report why they had downgraded the quality
of evidence
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the recent efforts of Cochrane to include this across all re-
views. Regardless of the decision of whether to downgrade
or not, this decision should be transparent from the onset
of the review, ideally in the protocol phase, and the justifi-
cation should be reported. Such was the case in all
Cochrane reviews in line with recommendations from the
GRADE Working Group [12]; however, the justifications
provided often lack detail to clearly follow the reasoning
of the judgement. In contrast, only 54% (n = 13) of
non-Cochrane reviews had assessed the quality of evi-
dence. For reviews that rated randomised trials as high/
unclear ROB for sequence generation, it might be difficult
to ascertain how this did or did not affect the conclusions
of a review if they did not conduct a formal quality of evi-
dence assessment.
This study examined only the sequence generation do-
main of the ROB assessment. Selection bias can be intro-
duced by an inadequate sequence, but can also result from
inadequate or absence of allocation concealment or blind-
ing. Further research could look at these domains in com-
bination. For the findings regarding the quality of evidence,
it was not possible to assess the appropriateness, or not, of
downgrading the quality of evidence because of the inclu-
sion of studies of high ROB for sequence generation, since
this decision is based on multiple factors, not all examined
in this study and often not reported in reviews.
Conclusions
Cochrane and non-Cochrane systematic reviews of inter-
ventions frequently rate randomised trials as high or un-
clear ROB for sequence generation. Just under half of
non-Cochrane reviews did not conduct a quality of evi-
dence assessment, but all Cochrane reviews did. It is im-
portant for the scientific community to increase efforts
promoting consistency and transparency in the ROB and
quality of evidence assessment in systematic reviews to
minimise bias in the review process. A structured ap-
proach to conducting systematic reviews (such as in
Cochrane reviews) and to assessing the quality of evi-
dence may provide more transparency in the reviews’
conclusions, which is critical given that systematic re-
views are frequently used to guide clinical practice. Our
findings emphasise the importance of good reporting in
primary studies to facilitate the review process.
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Table 5 Quality of evidence and sensitivity analysis in non-Cochrane reviews
Rated any
randomised trials
as high/unclear
ROB for sequence
generation)
Quality assessment using GRADE Quality assessment using a tool other than GRADE Conducted sensitivity
analysis based on ROBDowngraded for study
limitations (not specified)
Downgraded for study
limitations (selection bias)
Downgraded for study
limitations (not specified)
Downgraded for study
limitations (selection bias)
Non-Cochrane
reviews (n = 24)a
1 (4.2%) 2 (8.3%) 2 (8.3%) 0 1 (4.2%)
aEleven of the 24 (45.8%) reviews did not conduct any assessment of quality of evidence; 1 of the 24 (4.2%) reviews did not downgrade at all and
rated quality of evidence as high; 7 of the 24 (29.2%) reviews only downgraded for factors other than selection bias despite risk of bias being part
of the assessment tool used
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